Literature DB >> 27292583

Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.

Anita D'Souza1, Marcelo Pasquini1, Brent Logan1, Sergio Giralt2, Amrita Krishnan3, Joseph Antin4, Alan Howard5, Stacy Goodman6, Muzzafar Qazilbash7, Kristin Knust8, Firoozeh Sahebi3,9, Daniel Weisdorf10, David Vesole11, Edward Stadtmauer12, David Maloney13, Parameswaran Hari1.   

Abstract

Entities:  

Keywords:  freelite; hevylite; myeloma

Mesh：

Substances：

Year:  2016        PMID： 27292583      PMCID： PMC5154782          DOI： 10.1111/bjh.14170

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  10 in total

1.  Prognostic impact of serum immunoglobulin heavy/light chain ratio in patients with multiple myeloma in complete remission after autologous stem cell transplantation.

Authors:  Natalia Tovar; Carlos Fernández de Larrea; Montserrat Elena; M Teresa Cibeira; Juan I Aróstegui; Laura Rosiñol; Xavier Filella; Jordi Yagüe; Joan Bladé
Journal:  Biol Blood Marrow Transplant       Date:  2012-03-16       Impact factor: 5.742

2.  Erratum: Boyle EM, Fouquet G, Guidez S, Bonnet S, Demarquette H, Dulery R, Herbaux C, Noel MP, Manier S, Schraen S, Onraed B, Faucompre J-L, Hennache B, Petillon MO, Mathiot C, Avet-Loiseau H, Facon T, Harding SJ, Moreau P and Leleu X. IgA kappa/IgA lambda heavy/light chain assessment in the management of patients with IgA myeloma. Cancer. doi: 10.1002/cncr.28946.

Authors: 
Journal:  Cancer       Date:  2015-03-01       Impact factor: 6.860

3.  A window into immunoglobulin quantitation and plasma cell disease: antigen epitopes defined by the junction of immunoglobulin heavy and light chains.

Authors:  J A Katzmann; S V Rajkumar
Journal:  Leukemia       Date:  2013-01       Impact factor: 11.528

4.  Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial.

Authors:  Amrita Krishnan; Marcelo C Pasquini; Brent Logan; Edward A Stadtmauer; David H Vesole; Edwin Alyea; Joseph H Antin; Raymond Comenzo; Stacey Goodman; Parameswaran Hari; Ginna Laport; Muzaffar H Qazilbash; Scott Rowley; Firoozeh Sahebi; George Somlo; Dan T Vogl; Daniel Weisdorf; Marian Ewell; Juan Wu; Nancy L Geller; Mary M Horowitz; Sergio Giralt; David G Maloney
Journal:  Lancet Oncol       Date:  2011-09-29       Impact factor: 41.316

5.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

6.  Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Authors:  J A Katzmann; R Clark; R A Kyle; D R Larson; T M Therneau; L J Melton; J T Benson; C L Colby; A Dispenzieri; O Landgren; S Kumar; A R Bradwell; J R Cerhan; S V Rajkumar
Journal:  Leukemia       Date:  2012-07-11       Impact factor: 11.528

7.  Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Authors:  Joaquín Martínez-López; Bruno Paiva; Lucía López-Anglada; María-Victoria Mateos; Teresa Cedena; María-Belén Vidríales; María Auxiliadora Sáez-Gómez; Teresa Contreras; Albert Oriol; Inmaculada Rapado; Ana-Isabel Teruel; Lourdes Cordón; María Jesús Blanchard; Enrique Bengoechea; Luis Palomera; Felipe de Arriba; Cecilia Cueto-Felgueroso; Alberto Orfao; Joan Bladé; Jesús F San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2015-06-18       Impact factor: 22.113

8.  A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome.

Authors:  M Attal; J L Harousseau; A M Stoppa; J J Sotto; J G Fuzibet; J F Rossi; P Casassus; H Maisonneuve; T Facon; N Ifrah; C Payen; R Bataille
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

9.  Prognostic utility of intact immunoglobulin Ig'κ/Ig'λ ratios in multiple myeloma patients.

Authors:  A Bradwell; S Harding; N Fourrier; C Mathiot; M Attal; P Moreau; J-L Harousseau; H Avet-Loiseau
Journal:  Leukemia       Date:  2012-06-13       Impact factor: 11.528

10.  Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Authors:  H Ludwig; D Milosavljevic; N Zojer; J M Faint; A R Bradwell; W Hübl; S J Harding
Journal:  Leukemia       Date:  2012-07-17       Impact factor: 11.528
  10 in total
  2 in total

1.  Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients.

Authors:  M Michallet; C Chapuis-Cellier; T Dejoie; C Lombard; H Caillon; M Sobh; P Moreau; M Attal; H Avet-Loiseau
Journal:  Leukemia       Date:  2017-06-30       Impact factor: 11.528

2.  [The value of serum heavy/light chain immunoassay to assess therapeutic response in patients with multiple myeloma].

Authors:  X C Yu; W Su; J L Zhuang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.